A Single Center, Single Arm Clinical Study on the Treatment of Advanced Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations and Failed EGFR TKIs With the Combination of Enrotinib and Paclitaxel Monoclonal Antibody

Launched by DEGAN LU · Sep 15, 2023

Keywords

ClinConnect Summary

This clinical trial is exploring a new treatment approach for patients with advanced non-small cell lung cancer (NSCLC) who have specific genetic changes called EGFR-sensitive mutations and have not responded to previous therapies known as EGFR TKIs. The study will look at the effectiveness and safety of combining two drugs: anlotinib, which helps stop tumors from growing, and penpulimab, which boosts the immune system’s ability to fight cancer. The goal is to see if this combination can help patients live longer without their cancer worsening.

To participate, individuals must be between 18 and 75 years old, have been diagnosed with advanced NSCLC, and have already tried EGFR TKI treatment without success. They should not have had any other major treatments recently and must meet certain health criteria, such as having good blood and liver function. Participants can expect to take the study medications and undergo regular check-ups to monitor their health and the effectiveness of the treatment. This trial is not yet recruiting patients, but it aims to provide more effective options for those struggling with advanced NSCLC who have limited treatment choices.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Volunteer to participate in clinical research, aged 18-75 years old, regardless of gender, and sign a written informed consent form.
• • According to the International Association for the Study of Lung Cancer and the Joint Committee on the American Classification of Cancer, 8th edition TNM staging of lung cancer, locally advanced or metastatic (IIIB, IIIC, IV) NSCLC patients who are confirmed by histology or cytology to be inoperable and unable to undergo radical synchronous radiotherapy and chemotherapy.
• • NSCLC patients who have tested positive for EGFR gene sensitive mutations through driver gene testing and have not undergone systematic treatment after EGFR TKI treatment failure.
• • Newly treated patients who have not received systemic radiotherapy and chemotherapy in the past, or patients who have relapsed after more than 6 months of follow-up after adjuvant chemotherapy after surgery.
• • At least one evaluable lesion judged according to RECIST criteria.
• • Men or women aged 18 years ≤ 75 years old.
• • ECOG PS 0 or 1.
• • The expected survival period is ≥ 12 weeks.
• • Adequate blood function: Absolute neutrophil count (ANC) ≥ 1.5 × 109/L and platelet count ≥ 90 × 109/L and hemoglobin ≥ 9 g/dL.
• • Adequate liver function: Serum bilirubin ≤ 1.5 times the upper limit of normal value (ULN); AST and ALT ≤ 2.5 times the upper limit of normal value (ULN); Alkaline phosphatase ≤ 5 times the upper limit of normal value (ULN).
• • Adequate renal function: serum creatinine ≤ upper limit of normal (ULN) or calculated creatinine clearance rate ≥ 60 mL/min.
• • Women of childbearing age must have negative pregnancy test results within 28 days prior to enrollment in the study (unless amenorrhea has occurred for 24 months). If the pregnancy test is more than 7 days after the first administration, a urine pregnancy test is required for validation (within 7 days before the first administration).
• • If there is a risk of conception, all patients (whether male or female) are required to use contraceptive measures with an annual failure rate of less than 1% throughout the entire treatment period until 120 days after the last study drug administration.
• Exclusion Criteria:
• • Known hypersensitivity to any component contained in the formulation of arotinib or piazepril monoclonal antibody;
• • Individuals who are intolerant to the treatment of investigational drugs or are known to be allergic to any investigational drug or its excipients.
• • Pregnant or lactating women, or female patients with fertility who have not taken contraceptive measures;
• • Existing severe acute infections that have not been controlled; Those who may have purulent or chronic infections, and the wound persists without healing;
• • Individuals with previously severe heart disease, including congestive heart failure, uncontrollable high-risk arrhythmia, unstable angina, myocardial infarction, severe heart valve disease, and refractory hypertension;
• • Those who suffer from uncontrollable neurological, mental disorders or mental disorders, have poor compliance, and are unable to cooperate and describe treatment responses; Patients with primary brain tumors or central nervous system metastases whose condition has not been controlled and who have obvious intracranial hypertension or neuropsychiatric symptoms;
• • Have coagulation dysfunction or bleeding tendency, or have a history of thrombotic or hemorrhagic diseases;
• • Those undergoing anticoagulation or thrombolysis treatment;
• • There are unhealed wounds, ulcers, or fractures;
• • Currently participating in interventional clinical research treatment, or receiving other research drugs or using research instruments within 4 weeks before the first administration;
• • Has undergone major surgical treatment (excluding surgery for biopsy purposes) within 4 weeks prior to the first study drug administration, or is expected to undergo major surgery during the study period;
• • Pulmonary interstitial fibrosis with respiratory failure;
• • Patients with chronic obstructive pulmonary disease and respiratory failure;
• • Based on chest imaging examination, sputum examination, and clinical examination, it is determined that there is active pulmonary tuberculosis (TB) infection;
• • Patients with active, known or suspected autoimmune diseases. Patients with hypothyroidism who only require hormone replacement therapy can be selected;
• • Patients who require systemic corticosteroids (with a dose equivalent to\>10 mg prednisone/day) or other immunosuppressive drugs within the 14 days prior to enrollment. Patients who use inhaled or topical corticosteroids, as well as patients with adrenal corticosteroid replacement therapy doses equivalent to\>10 mg prednisone/day, may participate in the study if there is no active autoimmune disease;
• • Previously received PD-1 or PD-L1 antibody treatment for any reason;
• • Suffering from other primary malignant tumors before the start of the study;
• • Other situations where the researcher believes that patients are not suitable to participate in this trial.